scPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

CouponFollow Extension

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

scpharma.com

24%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · For the third quarter ended September 30, 2024, scPharmaceuticals reports: Net FUROSCIX revenue of $10.0 million, representing a 24% increase from the second quarter of …

yahoo.com

$91
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term …

streetinsider.com

164%
OFF

ScPharmaceuticals Inc. Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · Generated 3Q 2024 net FUROSCIX®revenue of $10.0 million, up 164% from Q3 2023 scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides …

bakersfield.com

$0.44
OFF

ScPharmaceuticals (SCPH) Earnings Date And Reports 2024

1 week from now

3 days ago · scPharmaceuticals announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.44, which hit analysts' consensus estimates of -$0.44. Quarterly revenue was …

marketbeat.com

$17
OFF

ScPharmaceuticals Inc. Reports Second Quarter 2024 Financial …

1 week from now

Aug 14, 2024 · scPharmaceuticals reported a net loss of $17.1 million for the second quarter of 2024, compared to $14.2 million for the second quarter of 2023. scPharmaceuticals ended the …

yahoo.com

$5
OFF

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

1 week from now

3 days ago · Summary of Financial Results for the Third Quarter 2024 The net loss for the three months ended September 30, 2024 was approximately $5.6 million compared to …

morningstar.com

$64
OFF

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Net Loss: Net loss for the third quarter of 2024 was $64.8 million, or $0.18 per share, as compared to a net loss of $50.5 million, or $0.21 per share, in the corresponding period in …

morningstar.com

8%
OFF

Molina Healthcare Reports Third Quarter 2024 Financial Results

1 week from now

Oct 23, 2024 · Quarter Highlights. As of September 30, 2024, the Company served approximately 5.6 million members, an increase of 8% compared to September 30, 2023.; Premium revenue …

molinahealthcare.com

$85
OFF

Capricor Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

4 days ago · Third Quarter 2024 Financial Results . Cash position: Cash, cash equivalents and marketable securities totaled approximately $85.0 million as of September 30, 2024 compared …

capricor.com

$3
OFF

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results …

1 week from now

5 days ago · As of September 30, 2024, cash equivalents totaled $3.0 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $6.6 million for the …

nasdaq.com

$76
OFF

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

4 days ago · Third Quarter 2024 Financial Results. As of September 30, 2024, Milestone had cash, cash equivalents, and short-term investments of $76.4 million, compared to $66.0 million …

biospace.com

$14
OFF

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to …

businessinsider.com

56%
OFF

Marinus Pharmaceuticals Provides Business Update And Reports …

1 week from now

5 days ago · ZTALMY ® (ganaxolone) Oral Suspension CV. Generated net product revenue of $8.5 million for the third quarter of 2024 representing 56% growth versus the third quarter of …

yahoo.com

FAQs about scPharmaceuticals Inc. Reports Third Quarter 2024 Financial … Coupon?

How did scpharmaceuticals perform in the second quarter of 2024?

scPharmaceuticals reported a net loss of $17.1 million for the second quarter of 2024, compared to $14.2 million for the second quarter of 2023. scPharmaceuticals ended the second quarter of 2024 with $38.5 million in cash, cash equivalents and short-term investments, compared to $76.0 million as of December 31, 2023. ...

Why did scpharmaceuticals' net loss increase in Q3 2024?

The increase in net loss for the third quarter of 2024, was primarily due to one-time charges related to the extinguishment of debt and accounting for the new financial instruments scPharmaceuticals entered into in August 2024. scPharmaceuticals’ net loss for the third quarter of 2024 was $0.75 per share. ...

How much does scpharmaceuticals charge per share?

The $0.75 per share was burdened by one-time charges of $0.47 per share. scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents, compared to $76.0 million in cash, cash equivalents, and short-term investments as of December 31, 2023. ...

What time does scpharmaceuticals hold a conference call?

Conference call and webcast information scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2024 results today, Wednesday, November 13 th, at 4:30 p.m. EST. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13749995. ...

Where can I find a replay of a scpharmaceuticals conference call?

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use ...

What did Marinus Pharmaceuticals do in the third quarter 2024?

RADNOR, Pa., November 12, 2024 -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. ...